US Patent 7132238 Method of determining a chemotherapeutic regimen based on ERCC1 expression

Patent 7132238 was granted and assigned to Response Genetics on November, 2006 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Response Genetics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

71322380

Patent Inventor Names

Kathleen D. Danenberg0

Date of Patent

November 7, 2006

Patent Application Number

104537840

Date Filed

June 4, 2003

Patent Primary Examiner

‌

Kenneth R Horlick

Patent abstract

The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and determine a platinum-based chemotherapy by examination of the amount of ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level. More specifically, the invention provides to oligonucleotide primer pair ERCC1 and methods comprising their use for detecting levels of ERCC1 mRNA.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7132238 Method of determining a chemotherapeutic regimen based on ERCC1 expression

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API